Immunogenicity and safety of a novel formalin-inactivated and alum-adjuvanted candidate subunit vaccine for mumps

Vaccine

Volumn 26, Issue 33, 2008, Pages 4276-4283

  Liang, Yan ^a   Ma, Shaohui ^a   Yang, Zijiang ^a   Liu, Longding ^a   Wang, Lichun ^a   Wang, Jingjing ^a   Jiang, Li ^a   Shi, Changjun ^a   Dong, Chenghong ^a   Li, Qihan ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

Author keywords

Immunity; Mumps vaccine; Purified antigen; Safety

Indexed keywords

ALUMINUM POTASSIUM SULFATE; FORMALDEHYDE; GAMMA INTERFERON; HN PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; LIVE VACCINE; MUMPS VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PURIFICATION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; MUMPS; MUMPS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; DISINFECTANTS; FEMALE; FORMALDEHYDE; HN PROTEIN; HYPERSENSITIVITY; MACACA MULATTA; MALE; MUMPS; MUMPS VACCINE; MUMPS VIRUS; NEUTRALIZATION TESTS; PAROTID GLAND; VACCINES, SUBUNIT; VIRUS INACTIVATION;

EID: 47149084165     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.060     Document Type: Article

References (27)

1. Galazka A.M., Kraigher A., and Robertson S.E. Mumps and mumps vaccine: a global review. Bull World Health Organ 77 1 (1999) 3-14
2. Caplan C.E. Mumps in the era of vaccines. CMAJ 160 6 (1999) 865-866
3. CDC. Mumps-United States, 1985-1988. MMWR 38 7 (1989) 101-105
4. Chen Z. Mumps virus and the vaccines. Chin J Vac Immun 10 2 (2004) 120-124
5. WHO. Mumps virus vaccines. Wkly Epidemiol Rec 76 (2001) 346-355
6. Ellenberg S.S., and Chen R.T. The complicated task of monitoring vaccine safety. Public Health Rep 112 1 (1997) 10-21
7. Bloom S., and Wharton M. Mumps outbreak among young adults in UK. Br Med J 331 7508 (2005) 363-364
8. CDC. Mumps epidemic-United Kingdom, 2004-2005. MMWR 55 7 (2006) 173-175
9. CDC. Update: multistate outbreak of Mumps-United States, January 1-May 2, 2006. MMWR Morb Mortal Wkly Rep 55 20 (2006) 559-563
10. Gemmill I.M. Mumps vaccine: is it time to re-evaluate our approach?. CMAJ 175 5 (2006) 491-492
11. Jefferson T., Price D., Demicheli V., and Bianco E. Unintended events following immunization with MMR: a systematic review. Vaccine 21 25-26 (2003) 3954-3960
12. Miller E., Goldacre M., Pugh S., Colville A., Farrington P., Flower A., et al. Risk of aseptic meningitis after measles, mumps and rubella vaccine in UK children. Lancet 341 8851 (1993) 979-982
13. Sugiura A.Y.A. Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis 10 (1991) 209-213
14. Magdzik W. Certain problems with limits of immunity against measles, mumps and rubella. Przegl Epidemiol 47 1-2 (1993) 47-53
15. Dacunha S.S., Rodrigues L.C., Barreto M.L., and Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine 20 7-8 (2002) 1106-1112
16. Dasilveira C.M., Kmetzsch C.I., Mohrdieck R., Spreb A.F., and Prevots D.R. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine. Int J Epidemiol 31 5 (2002) 978-982
17. Miller C., Miller E., Rowe K., Bowie C., Judd M., and Walker D. Surveillance of symptoms following MMR vaccine in children. Practitioner 233 1461 (1989) 69-73
18. WHO. Safety of mumps vaccine strains. Wkly Epidemiol Rec 82 (2007) 17-24
19. David T., Karzon M.D., David M.D., and Warren M.D. Immunization with inactivated measles virus vaccine: effect of booster dose and response to natural challenge. Pediatrics 36 1 (1965) 40-50
20. Kim H.W., Canchola J.G., Brandt B.D., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 (1969) 422-434
21. Huang ZX, Hong T, Liu CB. Medical viral basis and experimental technology. Beijing Science Publication. 1990; 551.
22. Ma S.H., Zhang R.S., Liu L.D., Wang J.J., Wang L.C., Yang W.J., et al. Sequence analysis of the SH gene and its flanking region of an isolated mumps virus (SP strain). J Microb Infect 1 2 (2006) 87-90
23. Nossal G.J. Inactivated measles vaccine and the risk of adverse events. Bull World Health Organ 78 2 (2000) 224-225
24. Liang L., Wang J., Xu J.H., and Zhang N.M. Epidemiological analysis of mumps from 1997 to 2002 in Sichuan province. J Prev Med Inform 20 1 (2004) 12-13
25. Briss P.A., Fehrs L.J., Parker R.A., Wright P.F., Sannella E.C., Hutcheson R.H., et al. Sustained transmission of mumps in a high vaccined population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 169 1 (1994) 77-82
26. Mackenzie D.G., Craig G., Hallam N.F., Moore J., and Stevenson J. Mumps in a boarding school: description of an outbreak and control measure. Br J Gen Pract 56 528 (2006) 526-529
27. Mary B., Meyer M.S., William C., Stifler M.D., and Joseph J.M. Evaluation of mumps vaccine given after exposure to mumps, with special reference to the exposed adult. Pediatrics 37 2 (1966) 304-315